Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Their objective was to determine whether the site of GH and testosterone interaction on protein metabolism is primarily hepatic or extrahepatic.

Why It Was Studied

GH and testosterone both exert protein-anabolic effects and may act synergistically.

Liver and muscle are major sites of protein metabolism.

Who Took Part

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, men only.

In this open-label randomized crossover study, the impact on whole-body protein metabolism of oral (solely hepatic testosterone exposure) and transdermal (systemic testosterone exposure) testosterone replacement in the presence or absence of GH was compared.

How the Study Was Run

The design is described as randomized, open-label and crossover.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

GH and testosterone both exert protein-anabolic effects and may act synergistically.

Topics PubMed links to this paper include Administration, Cutaneous, Drug Combinations, Drug Interactions, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism and Liver.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.